Helix BioPharma Corp. (HBP)

Toronto
0.265
0.000(0.00%)
  • Volume:
    35,259
  • Bid/Ask:
    0.265/0.270
  • Day's Range:
    0.260 - 0.265
  • Type:Equity
  • Market:Canada
  • ISIN:CA4229101098
  • CUSIP:422910109

HBP Overview

Prev. Close
0.265
Day's Range
0.26-0.265
Revenue
-
Open
0.265
52 wk Range
0.23-1.16
EPS
-0.06
Volume
35,259
Market Cap
37.75M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
28,464
P/E Ratio
-
Beta
-0.18
1-Year Change
-71.51%
Shares Outstanding
142,471,169
Next Earnings Date
Mar. 17, 2022
What is your sentiment on Helix BioPharma Corp.?
or
Market is currently closed. Voting is open during market hours.

Helix BioPharma Corp. Company Profile

Employees
10
Market
Canada

Helix BioPharma Corp. (Helix) is an immuno-oncology company that is developing drug candidates for the prevention and treatment of cancer. Helix’s proprietary technological platforms include DOS47, V-DOS47 and L-DOS47. The DOS47 is an oncology platform that offers a debilitation and destruction of cancer cells by modulating the tumor microenvironment. DOS47 is designed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extracellular conditions that are believed to act to defend the tumor. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. The L-DOS47 drug molecule includes a specialized camelid-derived single domain antibody. V-DOS47 targets the vascular endothelial growth factor two receptor (VEGFR2) and can be used in several types of solid tumors.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellSellStrong SellStrong Sell
Technical IndicatorsBuyBuyStrong SellStrong SellStrong Sell
SummaryNeutralNeutralStrong SellStrong SellStrong Sell
  • it got approved by FDA From USA for new drugs
    0
    • Looks like some insiders know something we don't
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.